 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
NEORX CP, (NERX) Stock Rating Learn More
| Our Overall Rating on NEORX CP, NERX is Not Available | | NeoRx Corporation, a biotechnology company, engages in the development and commercialization of cancer therapy products. The company focuses on development of Picoplatin (NX473), a platinum compound, designed to improve efficacy of existing platinum therapeutics for cancer. Picoplatin, which is in phase II clinical trial stage, is used in solid tumor cancers, including lung cancer and colorectal cancer. NeoRx was formed in 1984 and is headquartered in Seattle, Washington. | | Our Not Available Rating on NERX was issued on 11/22/2008 |
NEORX CP Technical Rating
|
|
|
|
